Literature DB >> 8262739

Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma. A Canadian National Cancer Institute Clinical Trial Group study.

J A Maroun1, J Skillings, R MacCormick, M Potvin, G Wielgosz, J R Davidson, E Eisenhauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8262739     DOI： 10.1007/bf00874163

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  3 in total

1.  Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.

Authors:  W R Leopold; J M Nelson; J Plowman; R C Jackson
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

2.  Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937).

Authors:  C Erlichman; M Moore; I G Kerr; B Wong; E Eisenhauer; B Zee; L R Whitfield
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

3.  Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.

Authors:  H D Showalter; J L Johnson; J M Hoftiezer; W R Turner; L M Werbel; W R Leopold; J L Shillis; R C Jackson; E F Elslager
Journal:  J Med Chem       Date:  1987-01       Impact factor: 7.446
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.